Purpose: Caffeine shows wide interindividual pharmacokinetic (PK) variation, and therapeutic drug monitoring (TDM) may be needed. The PK profile of caffeine in Korean preterm neonates was investigated, and factors influencing the clearance of caffeine were analyzed. Methods: Fifty-nine preterm neonates receiving caffeine for apnea of prematurity were enrolled in the study (gestational age, 29.5±2.2 weeks and birth weight [BW], 1,318±358 g). Caffeine (20 mg/kg) was intravenously administered to each neonate as a loading dose, followed by a maintenance dose of 5-10 mg/kg/d. A total of 190 serum concentrations were measured for population PK analysis and modeling using nonlinear mixed-effects model (NONMEM ® ) software.
INTRODUCTION
Caffeine is a methylxanthine that acts as a nonspecific inhibitor of adenosine receptors and is used to wean patients from ventilatory support or as a treatment for apnea 1) . Premature neonates receive a loading dose of 20-80 mg/kg in the initial 30 minutes, followed by a maintenance dose of 5-20 mg/kg/d 24 hours later 2, 3) .
The therapeutic dose range is 8-20 µg/mL, with toxic effects occurring at doses exceeding 20 µg/mL 4) . Caffeine in teracts with drugs metabolized by the cytochrome P450 (CYP) 1A2 enzyme and is eliminated by renal excretion 4) . Therefore, caffeine pharmacokinetics (PK) may vary in neonates.
The PK profile of caffeine in neonates is characterized by a volume of distribution of 0.8-0.9 L/kg, which is larger than that of children or adults 4, 5) . In addition, the half-life of caffeine in
neonates is approximately 72-96 hours, which is longer than that of adults, and is further prolonged with decreased renal function. The kidney is the main pathway of caffeine clearance in neonates; thus, newborns have lower clearance rates than children or adults. The population PK data on neonates, especially premature neonates, have been reported for Chinese, Malaysian, and Caucasian populations; however, no population PK data on Koreans have been analyzed.
There are relatively fewer reports of the adverse effects of caffeine than there are for other drugs used for apnea treatment. Irritability, restlessness, jitteriness, and tachycardia can occur owing to central nervous system (CNS) and cardiovascular stimulation [6] [7] [8] . An increase in the caffeine levels in the body in creases its potency and toxicity accordingly 9) . Therefore, when caffeine is administered to premature neonates with unstable metabolism, therapeutic drug monitoring (TDM) is indispensable. This study analyzes the population PK, including serum concentration in preterm neonates who received caffeine for apnea of prematurity, and the factors affecting serum caffeine levels.
MATERIALS AND METHODS

Patients
The data were obtained retrospectively from medical records and routine caffeine monitoring of 57 hospitalized neonates 
Serum sampling and analysis
Actual sampling and treatment times were recorded by a nurse on a data sheet and were checked independently. The serum caffeine concentrations were assayed by chromatography/ mass spectrometry (MS) using an API 4000TM liquid chromatography-tandem MS (LC-MS/MS) system (Applied Biosystems, Foster City, CA, USA). The working assay range was 0.2-50 mg/ L, and the inaccuracy and between-day and within-day variance were <10% across this range. Samples containing >20 mg/L caffeine were diluted in drug-free serum and re-assayed.
PK model
The concentration time course of caffeine was described 
Statistical analysis
The continuous variables were presented as means±standard deviation (SD) and were compared using Student's t-test. The categorical variables were presented as percentages and frequencies and compared using the chi-square or Fisher's exact test. The risk factors were analyzed using multivariable linear regression analysis adjusted for GA and BW to estimate the odds ratios (ORs) with 95% confidence intervals (CIs). A P<0.05 was considered statistically significant.
RESULTS
The patient characteristics are described in Table 1 In the case of the 5 mg/kg administration group, the 6 and 129 samples with serum caffeine levels >20 and <20 mg/L (high and normal concentration groups), respectively, were compared.
The average BWs in the normal and high concentration groups were 1,784±466 g and 1,350±332 g, respectively, which differed significantly (P=0.026, Table 3 ). No significant differences were observed in GA (28.9 and 28.8 weeks for normal and high concentration groups, respectively, P=0.876, Table 3 ), postnatal age, birth weight, and Apgar score. In the univariate and multiple linear regression analyses (Table 4) , the BW was a significant parameter (P=0.024), whereas the GA, postconceptional age, and Apgar score were not significant. The PK parameters determined were clearance (0.033 L/h), the volume of distribution (0.371 L), 11) . In a previous study, the recommended loading dose of caffeine citrate was 20 mg/kg and the maintenance treatment (5 to 10 mg/kg once a day) should be administered orally or by intravenous infusion. In this study, the dosage interval was not adjusted based on postnatal age. Instead, a loading dose of 20 mg/kg caffeine was administered, followed by a maintenance dose of 5 mg/kg administered every 24 hours, and increased to 10 mg/kg based on the symptoms and serum caffeine levels.
Caffeine is metabolized in the liver by CYP1A2 12) . The metabolism of caffeine is limited in neonates because of their immature hepatic enzyme system; approximately 86% of caffeine dose is excreted unchanged in the urine 13, 14) . Therefore, physiological variables related to renal function would influence caffeine clearance in newborns. Several other factors including genetic variation in hepatic metabolic enzymes and caffeine receptors may also contribute to the variability in pharmacodynamic responses [15] [16] [17] . This study included neonates with normal AST, ALT, BUN, and creatinine levels, and excluded newborns with kidney or liver disease.
The serum concentration of caffeine should be monitored periodically, especially in critically ill neonates with unexplained adverse effects, and the therapeutic range is 8-20 mg/L 18, 19) . In a study of neonates with GA of 27.6 weeks, groups that maintained caffeine dosing at 5 and 20 mg/kg had a mean serum caffeine concentration of 14.7 µg/mL (4.8-25.1 µg/mL) and 47.4 µg/mL (18.9-79.8 µg/mL), respectively 2) . In another study, the mean serum caffeine levels of 75 preterm neonates were 11.8 µg/ mL (4.75-26.1 µg/mL), with less than 4% >20 µg/mL 20) . In this and half-life (22.6 h). Based on these results, a clearance formula for each population was obtained using the following formula: typical clearance=0.0293×(BW/70) 1.33 . The clearance was significantly correlated with the current weight, and the model was fitted with an OFV of 885.53 (Table 4) .
DISCUSSION
For over 20 years, caffeine has been successfully used to treat study, based on neonates at 29.5 weeks GA, the mean serum concentration was 15.48 µg/mL (7.8-33.0 µg/mL). Among the neonates receiving maintenance caffeine doses of 5 and 10 mg/ kg, 6 (3%) and 23 (12%) showed serum caffeine levels >20 µg/ mL. The blood concentration of caffeine varies, and careful monitoring for toxicity is required. The serum concentration of caffeine tends to be high in underweight neonates, and extra caution is required with this population.
Caffeine toxicity has not been reported at the therapeutic plasma concentrations required to treat apnea of prematurity.
Caffeine is a CNS and cardiovascular stimulant and has been associated with irritability, restlessness, jitteriness, tachycardia, and other cardiovascular effects 4) . Other side effects are feeding intolerance, increased urine output, and necrotizing enterocolitis 21) .
Serum caffeine levels >50 µg/mL have been associated with fever, tachypnea, hypertonia, vomiting, hyperglycemia, elevated BUN, leukocytosis, seizures, and other symptoms 4, 22) . In another study, the heart rate and caffeine serum concentrations were significantly correlated (P<0.05), which is consistent with the increased probability of tachycardia with increased caffeine serum concentration 23) . TDM monitoring should be considered in critically ill neonates with unexplained adverse effects such as tachycardia therefore it has been done in our institution and since the highest serum caffeine concentration was 33 µg/mL in our study, it was not possible to assess side effects at levels greater than 50 µg/mL. In this study, no definite adverse effects were found. Moreover, no cases of serum caffeine levels >50 µg/ mL were recorded, and with constant observation, the dosage proved to be safe.
It is widely known that drug disposition in premature neonates can differ markedly from that in older children and adults 19, 24) .
The half-life of caffeine in preterm neonates (<33 weeks GA) was 87 hours, compared to 72-96 hours in the term neonate group 20) . The elimination of caffeine was severely suppressed in premature neonates but increased nonlinearly after birth up to 6 weeks of age, and reached adult values at approximately 60 weeks postmenstrual age 2) . The caffeine half-life observed for neonates in this study was shorter than that reported in other studies, which may have been caused by differences in the postnatal days.
Individual estimates of clearance were obtained using the population estimates and a post hoc Bayesian analysis of the individual concentration measurements. The mean clearance estimate was 1.8 mL/h/kg, which was lower than the average clearance values (7.9-8.9 mL/h/kg) reported by other studies 20, 25, 26) . The estimate of the population mean volume of distribution of caffeine (748 mL/kg) is similar to values reported by other studies (911 mL/kg) 2, 27) . For estimation of the parameters in the preterm neonate population, the NONMEM program was used to assess the PK profile information for caffeine. The assessment showed that postnatal age, regardless of current weight, was the continual variable that yielded the best adjustment of data in a clearance model. Thomson et al. 27) modeled clearance as a simple function of current weight and postnatal age without the effect of any other covariate. Based on the analysis of the population PK of premature Korean neonates, the caffeine clearance was proven to be affected by current BW, in accordance with previous results. Using the proportional error model for the random effects parameters, this study showed an OFV of 885.53. The interindividual variability of clearance was 14.87%, and the residual variability was 18.44%. Moreover, the estimated values for the final parameters presented a typical pattern with a precision within acceptable limits for both the fixed and random effects parameters (<20 and <50%, respectively) 28) .
The limitations of this study are the small sample size and insufficient variation in sampling times. In addition, the study was retrospectively conducted, and the toxicity symptoms could not be verified.
A comparison of the PK data of Koreans with that of other ethnicities revealed similarities in the clearance and volume of distribution values. The neonates had lower BWs than normal, which may have increased the caffeine serum levels. Therefore, the caffeine blood levels should be carefully monitored only in neonates with low BW who have apnea or signs of toxicity.
